title: Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report.
abstract: BACKGROUND
  Imatinib, a tyrosine kinase inhibitor, is a major therapeutic option for the management of unresectable aggressive fibromatosis. Unfortunately, for most patients of low or very low average income countries, surgery often is the first treatment option. This is related to unavailability of chemotherapy or targeted therapy, and to a lack of financial resources or surgeons' lack of knowledge of other therapeutic options.
  
  
  METHODS
  In 2010, a 26-year-old Moroccan man was referred to our oncology and radiotherapy center by his surgeon for the management of a recurrent tumor of his right subscapularis muscle. Before his assessment in our center, two resections were performed by his surgeon after performing an incision biopsy and magnetic resonance imaging. Postoperative magnetic resonance imaging was performed and showed a right axillary nodule size 2.1cm regarding a collection with a residual tumor. We decided to administer imatinib 400mg daily by mouth. Clinical and magnetic resonance imaging evaluation were performed regularly and reported a stable tumor. We reported no adverse side effects to imatinib regarding Common Terminology Criteria for Adverse Events grading.
  
  
  CONCLUSIONS
  Recurrences are high during aggressive fibromatosis management. Systemic treatment with imatinib for unresectable or recurrent tumors with positive c-KIT could be the best therapeutic option. In our case report, the patient was stabilized with imatinib for 30 months and he had a very good quality of life.
authors.affiliation: Centre Mohammed VI pour le Traitement des Cancers, CHU Ibn Rochd, Casablanca, Morocco. daocl@yahoo.fr.
authors.forename: Abou
authors.initials: A
authors.lastname: Dao
authors.forename: Nadia
authors.initials: N
authors.lastname: Benchakroun
authors.forename: Hamza
authors.initials: H
authors.lastname: Jabir
authors.forename: Amina
authors.initials: A
authors.lastname: Taleb
authors.forename: Zineb
authors.initials: Z
authors.lastname: Bouchbika
authors.forename: Nezha
authors.initials: N
authors.lastname: Tawfiq
authors.forename: Hassan
authors.initials: H
authors.lastname: Jouhadi
authors.forename: Souha
authors.initials: S
authors.lastname: Sahraoui
authors.forename: Abdellatif
authors.initials: A
authors.lastname: Benider
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D018222:Desmoid Tumors / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008137:Longitudinal Studies; D008297:Male; D019042:Muscle Neoplasms / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D017006:Rotator Cuff / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate